%PDF-1.4
%
71 0 obj
<>
endobj
68 0 obj
<>
endobj
124 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2003-11-07T15:45:44Z
2024-03-28T22:54:58-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T22:54:58-07:00
application/pdf
Heather
2002-1026.dec
uuid:81129c62-1dd2-11b2-0a00-6d08275d6100
uuid:81129c64-1dd2-11b2-0a00-aa0000000000
endstream
endobj
57 0 obj
<>
endobj
58 0 obj
<>
endobj
72 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 43 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 45 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 47 0 R/Type/Page>>
endobj
27 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 49 0 R/Type/Page>>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 51 0 R/Type/Page>>
endobj
142 0 obj
[146 0 R]
endobj
143 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 420.3613 35.9844 Tm
(The Journal of Rheumatology 2003; 30:12)Tj
0 Tc 0 Tw -45.7952 -0.0313 Td
(2528)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.1 396.47 -10.84 re
f*
0.5 w
109.25 59.1 396.47 -10.84 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.09641 Tw 10 0 0 10 54 529.2616 Tm
(or the immunoregulatory role of sCD1d. Further examina-)Tj
0.0135 Tw 0 -1.2 TD
(tion of the sCD1d molecule \(V2\) at a protein level is neces-)Tj
-0.0002 Tc 0 Tw T*
[(sary)64.7 (.)]TJ
/T1_2 1 Tf
-0.00011 Tc 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 61.6 471.2616 Tm
[(1.)-550.1 (Porcelli S, )36.8 (Y)99.8 (ockey CE, Brenner MB, Balk SP)110.7 (. )54.8 (Analysis of )17.7 (T)-257.1 (cell)]TJ
1.45 -1.25 Td
(antigen receptor \(TCR\) expression by human peripheral blood CD4)Tj
0 Tc 0 Tw 5.2 0 0 5.2 291.1673 463.9016 Tm
(-)Tj
8 0 0 8 73.2 451.2616 Tm
(8)Tj
5.2 0 0 5.2 77.2 453.9016 Tm
(-)Tj
/T1_3 1 Tf
8 0 0 8 81.1304 451.2616 Tm
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.2 (/\247 )17.7 (T)-257.1 (cells demonstrates preferential use of several )17.7 (V\247 genes and)]TJ
-0.9913 -1.25 Td
[(an invariant )17.7 (TCR )]TJ
/T1_3 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.0251 Tw 8.1557 0 Td
(chain. J Exp Med 1993;177:1-16.)Tj
-9.6057 -1.25 Td
[(2.)-550.1 (Dellabona P)110.7 (, Padovan E, Casorati G, Brockhaus M, Lanzavecchia )54.8 (A.)]TJ
1.45 -1.25 Td
[(An invariant )17.7 (V)]TJ
/T1_3 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_1 1 Tf
-0.00011 Tc [0.2 (24-J)]TJ
/T1_3 1 Tf
0 Tc [-0.1 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (Q/V\2471)36.8 (1 )17.7 (T)-257.1 (cell receptor is expressed in all)]TJ
0 -1.25 TD
(individuals by clonally expanded CD4)Tj
0 Tc 0 Tw 5.2 0 0 5.2 197.086 413.9016 Tm
(-)Tj
8 0 0 8 198.8163 411.2616 Tm
(8)Tj
5.2 0 0 5.2 202.8163 413.9016 Tm
(-)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 206.6041 411.2616 Tm
[(T)-257.1 (cells. J Exp Med)]TJ
0 Tc 0 Tw -16.6755 -1.25 Td
[(1994;180:1)36.9 (171-6.)]TJ
-0.00011 Tc 0.02499 Tw -1.45 -1.25 Td
[(3.)-550.1 (Exley M, Garcia J, Balk SP)110.7 (, Porcelli S. Requirements for CD1d)]TJ
1.45 -1.25 Td
[(recognition by human invariant )17.7 (V)]TJ
/T1_3 1 Tf
0 Tc 0 Tw 13.6337 0 Td
(\002)Tj
/T1_1 1 Tf
[0.2 (24)]TJ
5.2 0 0 5.2 195.3164 383.9016 Tm
(+)Tj
8 0 0 8 198.249 381.2616 Tm
(CD4)Tj
5.2 0 0 5.2 213.3604 383.9016 Tm
(-)Tj
8 0 0 8 215.0907 381.2616 Tm
(CD8)Tj
5.2 0 0 5.2 230.2021 383.9016 Tm
(-)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 233.9898 381.2616 Tm
[(T)-257.1 (cells. J Exp)]TJ
0 Tc -20.0987 -1.25 Td
(Med 1997;186:109-20.)Tj
-0.00011 Tc -1.45 -1.25 Td
[(4.)-550.1 (Brossay L, Chioda M, Burdin N, et al. CD1d-mediated recognition)]TJ
1.45 -1.25 Td
(of an )Tj
/T1_3 1 Tf
0 Tc 0 Tw [-0.2 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [(-galactosylceramide by natural killer )17.7 (T)-257.1 (cells is highly)]TJ
T*
(conserved through mammalian evolution. J Exp Med)Tj
0 Tc 0 Tw T*
(1998;188:1521-8.)Tj
-0.00011 Tc 0.02499 Tw -1.45 -1.25 Td
[(5.)-550.1 (Spada FM, Koezuka )36.8 (Y)128.9 (, Porcelli SA. CD1d-restricted recognition of)]TJ
1.45 -1.25 Td
[(synthetic glycolipid antigens by human natural killer )17.7 (T)-257.1 (cells. J Exp)]TJ
0 Tc T*
(Med 1998;188:1529-34.)Tj
-0.00011 Tc -1.45 -1.25 Td
[(6.)-550.1 (Balk SP)110.7 (, Bleicher P)91.7 (A, )17.7 (T)69.9 (erhorst C. Isolation and characterization of a)]TJ
1.45 -1.25 Td
[(cDNA)-220.2 (and gene coding for a fourth CD1 molecule. Proc Natl )54.8 (Acad)]TJ
0 Tc T*
[(Sci USA)-220.1 (1989;86:252-6.)]TJ
-0.00011 Tc -0.0298 Tw -1.45 -1.25 Td
[(7.)-550.1 (Kojo )-54.9 (S, Adachi )-18 (Y)128.9 (,)-0.1 ( )-37.1 (T)69.9 (sutsumi A, )-54.8 (Sumida )-37.1 (T)74 (.)-0.1 ( Alternative )-54.8 (splicing )-54.8 (forms)]TJ
0.02499 Tw 1.45 -1.25 Td
(of the human CD1D gene in mononuclear cells. Biochem Biophys)Tj
0 Tc T*
[(Res Commun 2000;276:107-1)36.9 (1.)]TJ
-0.00011 Tc -1.45 -1.25 Td
[(8.)-550.1 (W)39.8 (ilson SB, Kent SC, Patton KT)73.9 (, et al. Extreme )17.7 (Th1 bias of)]TJ
0.00729 Tw 1.45 -1.25 Td
(invariant V)Tj
/T1_3 1 Tf
0 Tc 0 Tw (\002)Tj
/T1_1 1 Tf
[0.2 (24J)]TJ
/T1_3 1 Tf
[0.1 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.2 (Q )17.7 (T)-257.1 (cells in type 1 diabetes. Nature)]TJ
0 Tc 0 Tw -0.0001 -1.25 Td
(1998;391:177-81.)Tj
-0.00011 Tc 0.02499 Tw -1.45 -1.25 Td
[(9.)-550.1 (Kojo S, )54.8 (Adachi )36.8 (Y)128.9 (,)-0.1 ( Keino H, )17.7 (T)69.9 (aniguchi M, Sumida )17.7 (T)74 (. Dysfunction of)]TJ
1.45 -1.25 Td
[(T)-257.1 (cell receptor )54.8 (A)128.9 (V24AJ18+, BV1)36.8 (1+ double negative regulatory)]TJ
33 65.4085 Td
[(natural killer )17.7 (T)-257.1 (cells in autoimmune diseases. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
[(2001;44:1)36.9 (127-38.)]TJ
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(10.)-550.1 (Arnett FC, Edworthy SM, Bloch DA, et al. )17.7 (The )54.8 (American)]TJ
1.95 -1.25 Td
[(Rheumatism )54.8 (Association 1987 revised criteria for the classification)]TJ
T*
[(of rheumatoid arthritis. )54.8 (Arthritis Rheum 1987;31:315-24.)]TJ
-1.9131 -1.25 Td
[(1)36.8 (1)-0.1 (.)-550.1 (T)69.9 (an EM, Cohen )54.8 (AS, Fries JF)79.7 (, et al. )17.7 (The 1982 revised criteria for the)]TJ
1.9131 -1.25 Td
[(classification of systemic lupus erythematosus. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1982;25:1271-7.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(12.)-550.1 (V)59.8 (itali C, Bombardieri S, Jonsson R, et al. Classification criteria for)]TJ
1.95 -1.25 Td
[(Sjogren\325)54.8 (s syndrome: a revised version of the European criteria)]TJ
T*
[(proposed by the )54.8 (American-European Consensus Group. )54.8 (Ann Rheum)]TJ
T*
(Dis 2002;61:554-8.)Tj
-1.95 -1.25 Td
[(13.)-550.1 (Sumida )17.7 (T)74 (,)-0.1 ( )36.8 (Y)99.8 (onaha F)79.7 (, Maeda )17.7 (T)74 (, et al. )17.7 (T)-257.1 (cell receptor repertoire of)]TJ
1.95 -1.25 Td
[(infiltrating )17.7 (T)-257.1 (cells in lips of Sj\232gren\325)54.8 (s syndrome patients. J Clin)]TJ
T*
(Invest 1992;89:681-5.)Tj
-1.95 -1.25 Td
[(14.)-550.1 (Aarskog NK, )17.7 (V)110.8 (edeler CA. Real-time quantitative polymerase chain)]TJ
1.95 -1.25 Td
[(reaction. )54.8 (A)-220.1 (new method that detects both the peripheral myelin)]TJ
T*
[(protein 22 duplication in Charcot-Marie-T)69.7 (ooth type 1A)-220.1 (disease and)]TJ
T*
(the peripheral myelin protein 22 deletion in hereditary neuropathy)Tj
T*
(with liability to pressure palsies. Hum Genet 2000;107:494-8.)Tj
-1.95 -1.25 Td
[(15.)-550.1 (T)69.9 (akahashi K, Honeyman MC, Harrison LC. Impaired yield, )]TJ
1.95 -1.25 Td
(phenotype, and function of monocyte-derived dendritic cells in)Tj
T*
(humans at risk for insulin-dependent diabetes. J Immunol)Tj
0 Tc 0 Tw T*
(1998;161:2629-35.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(16.)-550.1 (Pickl )17.7 (WF)79.7 (, Majdic O, Kohl P)110.7 (, et al. Molecular and functional )]TJ
1.95 -1.25 Td
(characteristics of dendritic cells generated from highly purified)Tj
0 Tc 0 Tw T*
(CD14)Tj
5.2 0 0 5.2 356.3113 457.1693 Tm
(+)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 361.4439 454.5293 Tm
(peripheral blood monocytes. J Immunol 1996;157:3850-9.)Tj
-4.9805 -1.25 Td
[(17.)-550.1 (Nieda M, Nicol )54.8 (A, Koezuka )36.8 (Y)128.9 (, et al. )54.8 (Activation of human)]TJ
0 Tc 0 Tw 1.95 -1.25 Td
(V)Tj
/T1_3 1 Tf
[0.1 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (24NKT)-257.3 (cells by )]TJ
/T1_3 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (-glycosylceramide in a CD1d-restricted and)]TJ
0 Tc 0 Tw T*
(V)Tj
/T1_3 1 Tf
[0.1 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (24TCR-mediated manner)54.8 (. Hum Immunol 1999;60:10-9.)]TJ
-1.95 -1.25 Td
[(18.)-550.1 (T)69.9 (akahashi )17.7 (T)74 (, Chiba S, Nieda M, et al. )54.8 (Analysis of human )17.7 (V)-257.2 (alpha)]TJ
0 Tc 0 Tw 1.95 -1.25 Td
(24)Tj
5.2 0 0 5.2 345.2 407.1693 Tm
(+)Tj
8 0 0 8 348.1326 404.5293 Tm
(CD8)Tj
5.2 0 0 5.2 363.2439 407.1693 Tm
(+)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 368.3765 404.5293 Tm
[(NK )17.7 (T)-257.1 (cells activated by )]TJ
/T1_3 1 Tf
0 Tc 0 Tw [-0.3 (\002)]TJ
/T1_1 1 Tf
-0.00011 Tc [0.1 (-galactosylceramide-pulsed)]TJ
0.02499 Tw -3.897 -1.25 Td
(monocyte-derived dendritic cells. J Immunol 2002;168:3140-4.)Tj
-1.95 -1.25 Td
[(19.)-550.1 (Hamajima N, Saito )17.7 (T)74 (, Matsuo K, Kozaki K, )17.7 (T)69.9 (akahashi )17.7 (T)74 (,)-0.1 ( )17.7 (T)69.9 (ajima K.)]TJ
1.95 -1.25 Td
(Polymerase chain reaction with confronting two-pair primers for)Tj
T*
(polymorphism genotyping. Jpn J Cancer Res 2000;91:865-8.)Tj
-1.95 -1.25 Td
[(20.)-550.1 (Hamajima N. PCR-CTPP: a new genotyping technique in the era of)]TJ
1.95 -1.25 Td
[(genetic epidemiology)64.8 (. Expert Rev Mol Diagn 2001;1:1)36.8 (19-23.)]TJ
-1.95 -1.25 Td
[(21.)-550.1 (T)69.9 (suchiya N, Shiota M, )36.8 (Y)99.8 (amaguchi )54.8 (A, Ito K. Elevated serum level of)]TJ
1.95 -1.25 Td
[(soluble HLA)-220.2 (class I antigens in patients with systemic lupus )]TJ
T*
[(erythematosus. )54.8 (Arthritis Rheum 1996;39:792-6.)]TJ
-1.95 -1.25 Td
[(22.)-550.1 (Filaci G, Contini P)110.7 (, Brenci S, et al. Soluble HLA)-220.2 (class I and class II)]TJ
1.95 -1.25 Td
(molecule levels in serum and cerebrospinal fluid of multiple )Tj
T*
(sclerosis patients. Hum Immunol 1997;54:54-62.)Tj
-1.95 -1.25 Td
[(23.)-550.1 (Zavazava N, Kronke M. Soluble HLA)-220.2 (class I molecules induce)]TJ
1.95 -1.25 Td
[(apoptosis in alloreactive cytotoxic )17.7 (T)-257.1 (lymphocytes. Nat Med)]TJ
0 Tc 0 Tw T*
(1996;2:1005-10.)Tj
-0.00011 Tc 0.02499 Tw -1.95 -1.25 Td
[(24.)-550.1 (Eberl G, MacDonald HR. Rapid death and regeneration of NKT)]TJ
1.95 -1.25 Td
(cells in anti-CD3e-or IL-12-treated mice: a major role for bone)Tj
T*
[(marrow in NKT)-257.3 (cell homeostasis. Immunity 1998;9:345-53.)]TJ
/T1_0 1 Tf
0 Tc 0.0979 Tw -35.3375 60.9875 Td
[(T)91.9 (able 1. )]TJ
/T1_1 1 Tf
-0.00011 Tc 3.9795 0 Td
[(Summary of )17.7 (V1 and )17.7 (V2 \(sCD1d\) mRNA)-293.1 (expression in patients)]TJ
0.02499 Tw -3.9795 -1.25 Td
[(and healthy subjects \(HS\). Results are expressed as mean \261)-259.9 (SEM.)]TJ
6 -2.5 Td
[(n)-4019.9 (Relative Expression of mRNAs)-3394.8 (p)]TJ
0 Tw -6 -2.5 Td
(V1)Tj
0 Tc 0.02499 Tw 0.7 -1.25 Td
[(HS)-3772.2 (15)-8075.6 (1.2 \261)-259.8 (0.23)]TJ
T*
[(RA)-3661.1 (18)-8075.6 (0.5 \261)-259.8 (0.12)-6844 (0.1)36.9 (10)]TJ
T*
[(SLE)-3272.4 (10)-8075.6 (1.3 \261)-259.8 (0.34)-6825.6 (0.994)]TJ
T*
[(SS)-3938.2 (15)-8094 (0.8 \261)-259.8 (0.1)36.9 (1)-6844 (0.595)]TJ
-0.00011 Tc 0 Tw -0.7 -1.25 Td
(V2)Tj
0 Tc 0.02499 Tw 0.7 -1.25 Td
[(HS)-3772.2 (15)-8075.6 (6.9 \261)-259.8 (2.08)]TJ
T*
[(RA)-3661.1 (19)-8075.6 (2.0 \261)-259.8 (0.33)-6825.6 (0.023)]TJ
T*
[(SLE)-3272.4 (10)-8075.6 (2.7 \261)-259.8 (0.48)-6825.6 (0.162)]TJ
T*
[(SS)-3938.2 (15)-8075.6 (4.3 \261)-259.8 (0.78)-6825.6 (0.473)]TJ
ET
54.5 696.9 m
293.5 696.9 l
55.5 676.9 m
295.5 676.9 l
54.5 564.9 m
293.5 564.9 l
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_4 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2003. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_5 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
51 0 obj
<>stream
8;Z\7$#[[H#ikq,j?(m=@iLTA2lb@WBXLPmKYnXo]"dgYT+Wr$4"ieLa0"l7q-+p:
TkW[oe@HKlQ1A\c<>pj@DjG^$^s/ul:r;+F_2Xj')10K"Bi<%JT&4OJ,qrqd&lkVI
HNQt0XEDYWWlm'6=n>_A0kVO#$8>&.?cTQ9+HS,si
6#b\SC<+\Cfd8\`i3cudfTWLT`.VR'25oQS*,qoi4]BCH[e9mR-&o9.dA/do'9>b9
.#s-Y;oM'h+0/r.S05\MO'hsaoQ2+u?c='e2'Gkd=`qTO)_E>b2Bm2C`O=PX
215[r=.Jl^QA_V3"(6&@%*]Fc?TE%DX0[i[XE\MbMi&K&?";GT7LMC>=1a.hfpM`P
QCVr/@>%)p!.u42/5"kpJN.R.69fQ"J;L^FIlI#Ll:*lT]2mSTY[E>tfS1WJ0e&8?7B,cu*ro,*-KMY6\J='AQ^OtO#+n'h8KB1>^
9-#ZURQ:aSJhsF[NB17mR>8s_CHePH5aAH]Y,[&7D/6/720'5k\(Wd$__B-JoAHL0
`.22'P`o:IhB>'i9;A^[H]R&d=j3"RqB/:jb>b:W%%bS6O-_6hiN.LT+al=30-cjJ
5-"#ClU&Xb_\e%qm)=8!'CG=JWN`86*;ZD(brZ3&A.FE,%SI\N9;S
(\%m.f)gq4NC=-"OC#ikPuh:;jaW2jb9KI\(8&`e:"so'\GlBub.RW\!-%CpJH~>
endstream
endobj
55 0 obj
[/Indexed/DeviceRGB 255 54 0 R]
endobj
54 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
77 0 obj
<>
endobj
76 0 obj
<>
endobj
85 0 obj
<>
endobj
38 0 obj
<>
endobj
113 0 obj
<>
endobj
129 0 obj
<>
endobj
41 0 obj
<>
endobj
39 0 obj
<>
endobj
42 0 obj
<>stream
HTPn0t䮆$6Et%= ˃GpI@W#&WE0bQehn~grMqø5j-p\h%` h =)-fIk^(݂3.2ti~ U#eZ9eFm1fj2_/
>%ȟ l
endstream
endobj
40 0 obj
<>stream
DJIDFL+Symbol . H H alphaSymbol a &!)qK^Nk=5I^^u ֻ̱lMM& hAc_KoBr`OO=,"[,32+_" //]՟ʴ%Gggydnt|zz|yumpqqruǠS
endstream
endobj
84 0 obj
<>
endobj
103 0 obj
<>stream
HLPgw /^TYcFwwZe,GuCE)TTJJHH@ՐD`Q)"VaAVElo@=n9mնy>v8;>yK!I+WxizKjhq3Ce>|^m*,ÚI12 (; ;haLL
BUT*<%,JL}AjVcYj.q
|谋RsBAHZlS6;bzH`q
&T4KLb`/2,6{i,L`Q9˶8-h1;|iT#H"ZG,3"L9%
~
]S@R]"H|J~EU4ɰorv*K"l%# vW9@Axc/w)z&I:e>`X\h]v`y=S
@-9IA[1x3 U0_*jO? 6ςhhhb 1{9|f蔷ߟA.[X/j8{4f6l;m=7У~V q@KE
|}t6FX}qW4Pde\nh;VO߰uAmT#`\ϴ%@=k
8;8P,T!hIMKp[Va̽)0$wf<{kW!c~TBDOEx NHGYٍ.ԝ$|GDs*cs~{yWkJ^-ݥ*^B{
6m(Л)I%($Ӓa}}~ݘP`@m8)s߬xsM+1%\u x!^okh~0'.%u8!אʧ'u%C/Y9 \W7 )hśd+խUA;Zro*گ9.xꤡNOt͗@++YC6x:*ߤMU"iz;WN["~<3t]~ݫ